This open-label Phase 1 study measures how a single dose of eloralintide is absorbed and handled by the body in people with mild, moderate or severe liver impairment compared with people whose livers work normally. It also records side effects. Each participant is in the study about 14 weeks. Sites are in the United States and Hungary.
Read with care: it is a clinical-pharmacology study, not a weight-loss study. A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.
Study context
What the study tests
This Phase 1 open-label study gives a single subcutaneous dose of eloralintide to people with mild, moderate or severe hepatic impairment and to people with normal liver function. The primary endpoints are the total drug exposure (AUC) and the peak concentration. The record lists 36 participants, and each is in the study for about 14 weeks, including a five-night stay at the research unit.
Who can take part
Adults aged 18 to 85 need a body weight of at least 55 kg and a BMI from 19 to 40. The impaired groups need chronic liver impairment for more than six months, classed as Child-Pugh A, B or C. People with hepatocellular carcinoma, grade 2 or higher hepatic encephalopathy or recent variceal bleeding are excluded. Sites are in Florida, Texas and Hungary.
What the registry does not say
No results are posted. The endpoints are drug-level measures, so the record says nothing about how eloralintide works in people with liver disease, only how the body handles it. Primary completion is registered for March 2027.
Source: ClinicalTrials.gov record NCT07401862, read on 2026-10-15. Registered plans can change.